alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 50 studies in BMC Medicine (page 2 of 2) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 57 out of 100. BMC medicine 2007-07-19

We observed that simvastatin is associated with a significant reduction in the incidence of dementia in subjects > or =65 years, using any of three models. 5 key findings →

Participants: 700,000 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The overlap between vascular disease and Alzheimer's disease--lessons from pathology

✓ Peer-reviewed alzhub usefulness score 56 out of 100. BMC medicine 2014-11-11

Recent epidemiological and clinico-pathological data indicate considerable overlap between cerebrovascular disease (CVD) and Alzheimer's disease (AD) and suggest additive or synergistic effects of both pathologies on cognitive decline. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association between chronic pain and risk of incident dementia: findings from a prospective cohort

✓ Peer-reviewed alzhub usefulness score 56 out of 100. BMC medicine 2023-05-04

Chronic musculoskeletal pain has been linked to dementia; however, chronic pain typically occurs in multiple sites; therefore, this study was to investigate whether greater number of chronic pain sites is associated with a higher risk of dementia and its subtypes. 4 key findings →

Participants: 356,383 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neighborhood environment associations with cognitive function and structural brain measures in older African Americans

✓ Peer-reviewed alzhub usefulness score 54 out of 100. BMC medicine 2025-01-13

Since older adults spend significant time in their neighborhood environment, environmental factors such as neighborhood socioeconomic disadvantage, high racial segregation, low healthy food availability, low access to recreation, and minimal social engagement may have adverse effects on cognitive function and increase susceptibility to dementia. 5 key findings →

Participants: 542 Evidence: low

Full summary, score breakdown and related studies → Original source

Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?

✓ Peer-reviewed alzhub usefulness score 53 out of 100. BMC medicine 2018-03-06

Intravitam PET and postmortem studies have revealed a more pronounced cortical atrophy, elevated cortical and limbic Lewy body pathologies, higher Aβ and tau loads in cortex and striatum in DLB compared to PDD, and earlier cognitive defects in DLB. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Trend analysis and future predictions of global burden of alzheimer’s disease and other dementias: a study based on the global burden of disease database from 1990 to 2021

✓ Peer-reviewed alzhub usefulness score 51 out of 100. BMC Medicine 2025-07-01

The global burden of AD and other dementias has significantly increased, with the highest incidence, prevalence, and DALYs observed in East Asia. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Prevalence of living alone with dementia and other progressive neurological conditions: findings from primary care data in England

✓ Peer-reviewed alzhub usefulness score 49 out of 100. BMC Medicine 2025-11-04

In 2023, there were 205,507 people with dementia in the CPRD database, 40,244 with Parkinson's disease, 3515 with MND and 1672 with Huntington's disease. 5 key findings →

Participants: 205,507 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The DSM-5 criteria, level of arousal and delirium diagnosis: inclusiveness is safer

✓ Peer-reviewed alzhub usefulness score 48 out of 100. BMC medicine 2014-10-08

Altered consciousness has been regarded as a core feature of delirium; the fact that consciousness itself should be physiologically disrupted due to acute illness attests to its clinical urgency. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Exploring the effect of pre-clinical Alzheimer’s disease on blood pressure using Mendelian randomisation and parental dementia as an instrumental variable in UK Biobank

✓ Peer-reviewed alzhub usefulness score 43 out of 100. BMC Medicine 2025-08-19

Both the higher parental dementia instrument and participant genetic instrument score were associated with higher mean SBP (difference in mean SBP mmHg per 1SD higher score: 0.12, 95% CI 0.06 to 0.17, p < 0.0001, and 0.07, 95% CI 0.00 to 0.13, p=0.037, respectively) but not DBP. 5 key findings →

Participants: 501,420 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Pinocembrin protects against β-amyloid-induced toxicity in neurons through inhibiting receptor for advanced glycation end products (RAGE)-independent signaling pathways and regulating mitochondrion-mediated apoptosis

✓ Peer-reviewed alzhub usefulness score 40 out of 100. BMC medicine 2012-09-18

Interaction between Aβ and the receptor for advanced glycation end products (RAGE) has been implicated in neuronal degeneration associated with this disease. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed